The development of immunotherapy in oncology field has revolutionized the prognosis of many types of cancer. The immune checkpoint inhibitors target receptors whose inhibition increases the activity of immune system cells against tumor cells. In recent years, new immunotherapies have been studied and approved in a growing number of tumors including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). This volume provides a complete and updated state-of-art review regarding the management of cardiovascular toxicities from new immunotherapies. The manuscript is divided into different sections starting from the relationship between cancer and immune system to let the reader understand the new molecular concepts under immunotherapy development. Subsequent chapters describe specifically the immunotherapy options in solid tumor treatment and the main features of the immuno-related cardiovascular complications. This volume is written by experts in the oncological and cardiovascular fields and aims to provide to clinicians who approach current cancer patients a useful tool to move through the paths of modern cardio-oncology. An important section would afford the most relevant interventions needed to manage the cardiac events, suggesting how to reduce their impact and effects on oncological outcomes. The text concludes by addressing future perspectives in the cardio-immunology field, discussing many aspects such as the early detection of cardiovascular damage and the potential role of liquid biopsy in new damage-related biomarkers discovery.

We are delighted to present the inaugural Frontiers in Cardiovascular Medicine “Rising Stars” article collection. This collection showcases the high-quality work of internationally recognized researchers in the early stages of their independent careers. All Rising Star researchers were individually nominated by the Chief Editors of the Journal in recognition of their potential to influence the future directions in their respective fields. The work presented here highlights the diversity of research performed across the entire breadth of cardiovascular medicine, including the elucidation of fundamental biology, the development of novel diagnostics or therapeutics, computational modelling approaches, and bioengineering strategies for regeneration.

Co-edited and written by an interdisciplinary team of experts in oncology and cardiology, this book is a clinically useful resource on these overlapping topics: • Cardiac complications in patients receiving cancer therapy • The treatment of cancer in patients with cardiovascular disease • The treatment of cardiovascular disease in patients with cancer When relevant to medical practice, epidemiology and basic science are also included in the discussion and each chapter is written by an oncologist and a cardiologist. Additionally, the chapters follow a similar format to make the book truly interdisciplinary, user-friendly, and clinically applicable to specialists and non-specialists who care for patients with both cancer and cardiovascular disease.

In this issue of Heart Failure Clinics, guest editors Drs. Ragavendra R Baliga and George A. Mensah bring their considerable expertise to the topic of Translational Research in Cardio-Oncology. Top experts in the field cover key topics such as radiation-induced cardiac dysfunction; training and career development; cardiovascular imaging; CAR-T cell therapy and cardiovascular disease; and more. - Contains 12 relevant, practice-oriented topics including cardio-protection of high-risk individuals; myocardial metabolism; amyloidosis; arrhythmic complications associated with cancer therapies; and more. - Provides in-depth clinical reviews on translational research in cardio-oncology, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.